BrightGene(688166.SH)

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; transfer of biomedical products; import, export, wholesale, and retail of medicines; production and operation of medical devices; and technical services.